We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-17.07%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.52B
AUM Growth
-$55.5M
Cap. Flow
+$168M
Cap. Flow %
11.04%
Top 10 Hldgs %
38.58%
Holding
149
New
11
Increased
70
Reduced
43
Closed
11

Top Buys

Rank Stock Value
1
ALGN icon
Align Technology
ALGN
+$41.6M
2
ILMN icon
Illumina
ILMN
+$33.2M
3
TDOC icon
Teladoc Health
TDOC
+$29.8M
4
ISRG icon
Intuitive Surgical
ISRG
+$25.9M
5
ABT icon
Abbott
ABT
+$14.7M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$17.1M
2
KTWO
K2M Group Holdings, Inc
KTWO
+$15.1M
3
EW icon
Edwards Lifesciences
EW
+$14.5M
4
PACB icon
Pacific Biosciences
PACB
+$13.9M
5
LH icon
Labcorp
LH
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 88.15%
2 Industrials 0.99%
3 Technology 0.52%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
101
Acadia Pharmaceuticals
ACAD
$4.38B
$1.55M 0.1%
95,800
+38,800
+68% +$753K
ANGO icon
102
AngioDynamics
ANGO
$558M
$1.52M 0.1%
75,700
– –
KYNB
103
Kyntra Bio
KYNB
$29.3M
$1.48M 0.1%
+1,280
New +$1.44M
PODD icon
104
Insulet
PODD
$11.4B
$1.43M 0.09%
18,000
– –
SRPT icon
105
Sarepta Therapeutics
SRPT
$1.82B
$1.39M 0.09%
12,700
-400
-3% -$50K
VCRA
106
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$1.3M 0.09%
+32,950
New +$1.19M
AMRX icon
107
Amneal Pharmaceuticals
AMRX
$5.7B
$1.28M 0.08%
95,000
– –
BLUE
108
DELISTED
bluebird bio
BLUE
$1.28M 0.08%
996
+116
+13% +$178K
ENDP
109
DELISTED
Endo International plc
ENDP
$1.24M 0.08%
170,392
-47,000
-22% -$645K
ARGX icon
110
argenx
ARGX
$53.8B
$1.21M 0.08%
+12,600
New +$1.12M
LOXO
111
DELISTED
Loxo Oncology, Inc
LOXO
$1.21M 0.08%
+8,600
New +$1.31M
ARNA
112
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.18M 0.08%
30,317
-500
-2% -$19.6K
MRK icon
113
Merck
MRK
$315B
$1.15M 0.08%
15,720
+2,620
+20% +$185K
MRTX
114
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.02M 0.07%
24,000
-1,000
-4% -$39.9K
SAGE
115
DELISTED
Sage Therapeutics
SAGE
$1.01M 0.07%
10,600
-600
-5% -$68.7K
RGNX icon
116
Regenxbio
RGNX
$534M
$977K 0.06%
23,300
– –
RARE icon
117
Ultragenyx Pharmaceutical
RARE
$2.88B
$965K 0.06%
22,200
-9,650
-30% -$527K
MYGN icon
118
Myriad Genetics
MYGN
$584M
$927K 0.06%
+31,900
New +$1.15M
TEVA icon
119
Teva Pharmaceuticals
TEVA
$37.3B
$925K 0.06%
60,000
– –
EVH icon
120
Evolent Health
EVH
$654M
$903K 0.06%
+45,270
New +$1.05M
LH icon
121
Labcorp
LH
$23.2B
$821K 0.05%
7,566
-101,897
-93% -$13.7M
IRWD icon
122
Ironwood Pharmaceuticals
IRWD
$635M
$793K 0.05%
91,341
-3,463
-4% -$39.7K
CLLS
123
Cellectis
CLLS
$265M
$778K 0.05%
46,750
-2,850
-6% -$66.1K
MCK icon
124
McKesson
MCK
$98.5B
$760K 0.05%
6,879
-1,624
-19% -$203K
ADAP
125
DELISTED
Adaptimmune Therapeutics
ADAP
$754K 0.05%
131,135
+72,600
+124% +$536K
2 3 4
5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2018 Portfolio in Review

As of Q4 2018, Bellevue Group held 149 positions worth $1.52B, down 3.5% from $1.58B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Bellevue Group deployed $168M of net new capital in Q4 2018, opening 11 new positions and adding to 70 existing holdings. Its largest new stake was QuidelOrtho: 125,000 shares worth $6.1M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 93% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Centene, an estimated $17.1M trimmed.

  • Bellevue Group's largest Q4 2018 buy was QuidelOrtho: 125,000 shares worth $6.1M.
  • Bellevue Group added most to Align Technology in Q4 2018, an estimated $41.6M increase.
  • Bellevue Group's biggest Q4 2018 reduction was Centene, cutting an estimated $17.1M.
  • Bellevue Group fully exited K2M Group Holdings, Inc in Q4 2018, selling an estimated $15.1M.
  • Bellevue Group's ten largest holdings make up 39% of its $1.52B portfolio in Q4 2018.
  • Bellevue Group opened 11 new positions and closed 11 in Q4 2018.
  • Bellevue Group's portfolio value fell 3.5% quarter-over-quarter to $1.52B.

Based on Bellevue Group's 13F filing for Q4 2018, filed 12 Feb 2019.